LSIPR 50 2018: Stephen Knight

Name: Stephen Knight

Organisation: F Prime Capital Partners

Position: Managing Director

Stephen Knight has been with F Prime Capital Partners since 2003, and he now serves as president and managing partner.

Bringing more than 25 years of experience in the pharmaceutical and biotechnology industries, he is well equipped to guide the global venture capital firm, which invests in the healthcare and technology sectors.

F Prime Capital Partners has been responsible for investing in numerous companies, including self-described “pioneer” in CRISPR-Cas9 genome editing, Caribou Biosciences, and Menlo Therapeutics, a late stage biopharmaceutical company focusing on dermatology.

Knight also serves on the board of directors of Innovent Biologics, Iora Health, Pulmocide and Semma Therapeutics.

Before becoming director, Knight served on the boards of several private and public healthcare companies, including Proteostasis Therapeutics, Denali Therapeutics, Blueprint Medicines and Ironwood Pharmaceuticals.

"Before becoming director, Knight served on the boards of several private and public healthcare companies."

During his career Knight has served in various senior management roles in private and public biotechnology and consulting companies.

His qualifications include doctor of medicine from the Yale University School of Medicine, an MBA from the Yale School of Organisation and Management and a bachelor of science in biology from Columbia University. Knight was also a researcher at the National Institutes of Health and Yale University.